Abstract
Patients with polycythemia vera (PV) have a high risk of thrombosis. However, thrombosis is not sufficiently predictable with standard diagnostic procedures. We report on a patient with PV and recurrent thrombosis who nevertheless had a low platelet count while under therapy with hydroxyurea. As a result of duodenal ulcer and gastrointestinal bleeding, treatment with phenprocoumon was stopped years ago. Recently, heterozygosity for the factor V gene defect was diagnosed and anticoagulation therapy was reconsidered. In conclusion, the presence of resistance to activated protein C was an additional thrombotic risk factor that was important for our decision to change the treatment strategy in our patient.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Received: 8 August 1996 / Accepted: 18 November 1996
Rights and permissions
About this article
Cite this article
Lamparter, S., Schuermann, M. & Heidtmann, HH. APC resistance as an additional thrombotic risk factor in a patient suffering from polycythemia vera and recurrent thrombosis. Ann Hematol 74, 49–50 (1997). https://doi.org/10.1007/s002770050256
Issue Date:
DOI: https://doi.org/10.1007/s002770050256